engleski

Factors influencing the selection of biological therapy in asthma

Asthma is a common ancient disease, still not well understood. Different therapy was applied trough history, with small benefit, until inhaled steroid (ICS) discovery in seventies of the last century, and long acting beta2-agonists (LABA) in nineties gave significant improvement. An enthusiasm flood physicians, not for long. It is recognized that even with regular usage of enough high ICS dosage, LABA, long -acting antimuscarinic agents (LAMA), leukotriene receptor antagonists, and/or theophylline , in patients who are adherent to therapy with good inhaled technique, without smoking, anxiety or obesity, with treated and controlled comorbidities , there are still asthma patients who suffer a lot (10% of them), or can’t achieve good asthma control – more than 30%. The answer came from immunologist in cooperation with clinicians. Asthma biomarkers and patient phenotypes are recognized as factors that could predict which asthma patient could ameliorate with biological therapy targeted to different part of immune reaction, like anti immunoglobulin E (IgE), or anti interleukin-5 (IL-5), or IL-4 and IL-13 therapy. If we use biological agent in right patient, the result are great, with less symptoms, less exacerbations, less drugs for asthma treatment and less side effects, better lung function, and improved quality of life.

Asthma-therapy

nije evidentirano